In one paragraphArticle in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Merlijn U J E GrausDivision of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, 6229 HX, The Netherlands.ORCID 0000-0002-3645-1458 Thijmen H T BroekmanDepartment of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, 1081 HZ, The Netherlands.ORCID 0009-0001-1992-4065 Sietske van NassauDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, 3584 CX, The Netherlands.ORCID 0000-0002-6763-6519 Nicol Pepels-AartsDivision of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, 6229 HX, The Netherlands.
Geert A CirkelDepartment of Medical Oncology, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Regional Academic Cancer Center Utrecht, Nieuwegein, 3430 EM, The Netherlands.ORCID 0009-0007-8712-9825 Marcel den DulkDepartment of Surgery, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Center, Maastricht University, Maastricht, 6229 HX, The Netherlands.ORCID 0000-0002-6161-161X Brigitte C M HaberkornDepartment of Medical Oncology, Maasstad Hospital, Rotterdam, 3079 DZ, The Netherlands.ORCID 0009-0006-6869-7264 Irene E G van HellemondDepartment of Medical Oncology, Catharina Hospital Eindhoven, Eindhoven, 5623 EJ, The Netherlands.ORCID 0000-0001-6775-7364 Karlijn E P E HermansDivision of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, 6229 HX, The Netherlands.ORCID 0000-0002-6184-0244 Marjolein Y V HomsDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, 3015 GD, The Netherlands.ORCID 0000-0001-9828-2541 Maartje LosDepartment of Medical Oncology, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Regional Academic Cancer Center Utrecht, Nieuwegein, 3430 EM, The Netherlands.ORCID 0000-0002-4953-5271 Saskia A C LuelmoDepartment of Medical Oncology, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands.ORCID 0000-0002-9298-2878 Sasja F MulderDepartment of Medical Oncology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, 6525 GA, The Netherlands.ORCID 0000-0002-8068-4240 Mirte M StreppelDepartment of Medical Oncology, Amphia Hospital, Breda, 4818 CK, The Netherlands.
Miriam L WumkesDivision of Medical Oncology, Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, 5223 GZ, The Netherlands.
Johanna W WilminkDepartment of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, 1081 HZ, The Netherlands.ORCID 0000-0002-1677-1278 Ignace H J T de HinghGROW-Research Institute for Oncology & Reproduction, Maastricht University, Maastricht, 6229 ER, The Netherlands.ORCID 0000-0003-3491-4268 Liselot B J Valkenburg-van IerselDivision of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, 6229 HX, The Netherlands.ORCID 0000-0003-2925-9908 Judith de Vos-GeelenDivision of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, 6229 HX, The Netherlands.ORCID 0000-0003-2578-1766 Dutch Pancreatic Cancer Group
Funding
Deltaplan Pancreatic Cancer and the Dutch Digestive Health Fund WOO 20-05Deltaplan Pancreatic Cancer and the Dutch Digestive Health Fund WOO 21-08
6 · The paper itselfAbstract
backgroundTreatment decisions in metastatic pancreatic adenocarcinoma (mPAC) involve complex tradeoffs between survival benefits and treatment burden. Shared decision-making (SDM) is crucial but challenging in emotionally charged and time-pressured consultations. This study evaluated the real-world implementation of a decision aid to support SDM in treatment decisions in mPAC care. MATERIALS AND
methodsIn this prospective, multicenter study across 10 Dutch expert centers, patients with mPAC and their clinicians used a newly-developed decision aid during consultations for treatment decisions. Data were collected on preferences, decision aid use, and final treatment choices, supplemented by surveys and interviews assessing feasibility and experiences. Outcomes included decision aid use, user experience, and concordance of final treatment decision with physician and patient preferences.
resultsA total of 68 clinicians participated and 227 patients were counseled using the decision aid, of whom 181 patients consented to participate in the implementation study, and 135 patients used the online decision aid. Patients who received consideration time were more likely to use the decision aid (P < 0.01). Both patients and clinicians rated the decision aid positively (median score 8/10). Discordance between physician and patient preferences regarding treatment decisions was observed in 37%.
conclusionA structured decision aid can be successfully implemented in real-world mPAC care and was highly valued by both patients and clinicians. Differences between clinician preference, patient preference, and ultimate treatment decision were frequently observed, highlighting the need to consider treatment decision-making as an ongoing process that allows time for reflection and dialogue.
Indexed as
AdenocarcinomaDecision Support TechniquesPancreatic NeoplasmsAgedDecision MakingDecision Making, SharedFemaleHumansMaleMiddle AgedNeoplasm MetastasisPatient ParticipationProspective Studiesdecision aidpancreas adenocarcinomaquality of lifeshared decision-makingtreatment concordance
What OpenQuestion holds
Textmetadata
Read underepoch 390